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It has been established that developmen-
tal regulators play a direct role in driving 
aspiring cancer cells towards a malignant 
phenotype. Inhibitors of DNA-binding/
differentiation family of proteins are 
dominant negative regulators of basic 
helix-loop-helix (bHLH) transcription 
factors. They play a key role during devel-
opment, preventing cell differentiation 
while inducing cell proliferation. They 
are poorly expressed in adult life but can 
be reactivated in tumorigenesis leading to 
alteration in cell cycle progression, senes-
cence and apoptosis.1,2
We have recently shown that mutant p53 
proteins specifically induce Id4 expression 
in breast cancer cells.3 Mutant p53 proteins, 
usually expressed at markedly elevated lev-
els in cancer cells, are associated with drug 
resistance and greater tumorigenicity.4-7 
We have shown that Id4 protein expression 
is enriched in breast cancer (BC) tissues 
showing p53 overexpression (predictive of 
the presence of mutant p53).3 The acti-
vation of Id4 promoter is driven by the 
transcriptional competent protein com-
plex mutant p53/E2F1/p300 and leads to 
an increase of the angiogenic potential of 
mutant p53-carrying tumor cells.3
We explored whether additional Id 
family members, besides Id4, were regu-
lated by mutant p53 and we found that 
Id2 expression was increased following 
p53R175H induction in H1299 lung ade-
nocarcinoma inducible cells. The increase 
was more pronounced in the presence of a 
DNA damaging agent, like cisplatin (Fig. 
1A). Id2 induction was also observed after 
infection with a retroviral vector expressing 
mutant p53R175H (Fig. 1B). To evaluate 
whether endogenous mutant p53 controls 
Id2 expression, we depleted p53 expression 
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in SKBr3 breast cancer cell line, carrying 
p53R175H. As shown in Figure 1C Id2 
expression is reduced by 35% after mutant 
p53 depletion in proliferating cells. We 
then analyzed Id2 promoter occupancy by 
Chromatin Immunoprecipitation (ChIP), 
amplifying a region upstream to Id2 tran-
scription start site (TSS), which contained 
binding sites for E2F (E2FF and CDE 
elements), NF-Y (CCAAT), NFκB and 
Sp1 (outlined in Fig. 1D). We found that 
mutant p53, p65 (NFκB), E2F1 and p300 
are recruited to this promoter region (Fig. 
1E) in proliferating SKBr3 cells. Given 
that we have previously demonstrated that 
mutant p53 is recruited to Id4 promoter 
regions by DNA-binding transcription 
factors,3,8 such as E2F1 and NFκB, we 
analyzed by ReChIP experiments whether 
these last mediate mutant p53 recruitment 
to Id2 promoter too. As shown in Figure 
1F mutant p53 is strongly associated to 
E2F1 and p300 on Id2 promoter.
We then analyzed Id2 mRNA levels 
in mutant p53-carrying cell lines after 
sub-lethal doses of DNA damage and we 
observed a strong induction in all the ana-
lyzed cell lines (Fig. 1G). This induction 
is mutant p53-dependent, as p53 deple-
tion in SW480 cells (carrying p53R273H/
P309S) reduces the induction of Id2 tran-
script (Fig. 1H). ChIP analyses in SW480 
untreated or after DNA damage showed 
that mutant p53 is bound with similar 
efficiency to Id2 promoter in both condi-
tions, while the binding of p65 and, more 
markedly, that of E2F1 is increased after 
DNA damage. ReChIP assay showed 
that mutant p53 is associated with p65 in 
untreated cells, while during DNA dam-
age mutant p53 is strongly and specifically 
associated only with E2F1.
ReChIP data obtained in SKBr3 and 
SW480 cells suggest that mutant p53 
cooperates with E2F1 in the control of 
Id2 promoter. A previous report by Yan et 
al. showed that Id2 is repressed by mutant 
p53 in proliferating SW480 cells.9 Here we 
show that under DNA damaging condi-
tion the mutp53/E2F1 complex positively 
controls Id2 expression in SW480 cells. 
These apparently contradictory findings 
might reflect the assembly of selective pro-
tein complexes, containing mutant p53, 
DNA-binding transcription factors and 
co-activators, such as p300 or PCAF, or 
co-repressors, such as HDACs, whose out-
put ranges from activation to repression.
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Figure 1. For figure legend, see page 2466.
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Figure 1 (See previous page). id2 is transcriptionally induced by mutant p53. (A) Quantitative rt-PCr (qrt-PCr) analysis of id2 mrNA expression on 
clone 41 (expressing inducible p53r175h), clone 23 (expressing inducible wild-type p53) and control clone (carrying the empty vector) in presence or 
absence of Ponasterone A and/or cisplatin. the following primers for id2 transcript detection were used: forward, 5'-GAC CAC CCt CAA CAC GGA tA; 
reverse, 5'-CAC ACA GtG Ctt tGC tGt CA. relative id2 mrNA levels were calculated by normalization for the amount of GAPdh transcript present in 
the rNA preparations. (B and C) qrt-PCr analysis of id2 mrNA expression in (B) h1299 cells infected with a retroviral vector expressing p53r175h,  
(C) SKBr3 cells depleted of mutant p53 expression. (d) Schematic representation of id2 promoter. (E) Cross-linked chromatin derived from proliferating 
SKBr3 cells was subjected to ChiP using the indicated antibodies. the occupancy of id2 promoter was analyzed by qPCr using the following primers: 
forward 5'-GAA CGC GGA AGA ACC AAG; reverse 5'-ttC CCt tCG tCC CCA ttG. (F) Four additional aliquots of chromatin immunoprecipitated with anti-
p53 antibody were eluted and re-immunoprecipitated with No Ab (as negative control) or with antibodies directed against p65, E2F1, p300 and PCAF. 
(G) qrt-PCr analysis of id2 expression in SKBr3, ht29 and SW480 cells following treatment with adriamycin (1 µM) for 36 hours. (h) qrt-PCr analysis 
of id2 mrNA expression in SW480 cells depleted of mutant p53 expression following treatment with adriamycin (1 µM) for 36 hours. (i) Cross-linked 
chromatin derived from SW480 cells treated (t) or not (Nt) with adriamycin (1 µM) for 36 hours was subjected to ChiP using the indicated antibodies. 
three additional aliquots of chromatin immunoprecipitated with anti-p53 antibody were eluted and re-immunoprecipitated with No Ab (as negative 
control) or with antibodies directed against p65 and E2F1.
